accessibility menu, dialog, popup

UserName
Viewing profile as user:

Peptides

Short chains of amino acids linked by peptide (amide) bonds. Peptides are used as catalysts, signaling ligands, and imaging agents; for biometric hydrogel construction, immunoprecipitation processes, and more.

Filtered Search Results

Products from some of our suppliers do not display in filtered search results. Please clear all filters to see these products.

Narrow Results

Narrow Results

category

brands

  • (1)
  • (4)

special interests

  • (5)

Search Within Results
Keyword Search:
1 – 5 of 5 results
1

Bachem Cyclo(-Gly-Phe)
SDP

Cyclo(-Gly-Phe), 10125-07-2, C11H12N2O2, Mr 204.23, 1g.

ENCOMPASS_PREFERRED
2

CPC Scientific H-Pro-Lys-Thr-Pro-Lys-Lys-Ala-Lys-Lys-Leu-OH (trifluoroacetate salt) 1MG
SDP

The native peptide PKTPKKAKKL is derived from the histone H1 peptide sequence that is docked in the active site of cyclin-dependent kinase 5. It is an effective CDK5 substrate (Km = 40 M).SEQUENCE: H-Pro-Lys-Thr-Pro-Lys-Lys-Ala-Lys-Lys-Leu-OH (trifluoroacetate salt)ONE-LETTER SEQUENCE: PKTPKKAKKLMOLECULAR FORMULA: C53H99N15O12MOLECULAR WEIGHT: 1138.45STORAGE CONDITIONS: -20 5 CCAS REGISTRY NUMBER: [164669-07-2]SYNONYMS: RESEARCH AREA: MiscellaneousREFERENCES:Lew, J. Biochem. 42, 849 (2003)Sharma, P. et al. J. Biol. Chem. 274, 9600 (1999)SKU(s): HIST-081A, HIST-081B

ENCOMPASS
3

CPC Scientific H-Pro-Lys-Thr-Pro-Lys-Lys-Ala-Lys-Lys-Leu-OH (trifluoroacetate salt) 5MG
SDP

The native peptide PKTPKKAKKL is derived from the histone H1 peptide sequence that is docked in the active site of cyclin-dependent kinase 5. It is an effective CDK5 substrate (Km = 40 M).SEQUENCE: H-Pro-Lys-Thr-Pro-Lys-Lys-Ala-Lys-Lys-Leu-OH (trifluoroacetate salt)ONE-LETTER SEQUENCE: PKTPKKAKKLMOLECULAR FORMULA: C53H99N15O12MOLECULAR WEIGHT: 1138.45STORAGE CONDITIONS: -20 5 CCAS REGISTRY NUMBER: [164669-07-2]SYNONYMS: RESEARCH AREA: MiscellaneousREFERENCES:Lew, J. Biochem. 42, 849 (2003)Sharma, P. et al. J. Biol. Chem. 274, 9600 (1999)SKU(s): HIST-081A, HIST-081B

ENCOMPASS
4

CPC Scientific H-Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys-OH (trifluoroacetate salt) 0.5MG
SDP

SEQUENCE: H-Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys-OH (trifluoroacetate salt)(Cys1 and 29 bridge, Cys3 and 18 bridge, Cys8 and 28 bridge)ONE-LETTER SEQUENCE: CYCRIPACIAGERRYGTCIYQGRLWAFCC (C1&C29 bridge, C3&C18 bridge, C8&C28 bridge)MOLECULAR FORMULA: C147H217N43O37S6MOLECULAR WEIGHT: 3370.95STORAGE CONDITIONS: -20 5 CCAS REGISTRY NUMBER: [99287-07-7]SYNONYMS: -Defensin-2 (Human), alpha-Defensin-2 (Human), Defensin HNP-2 humanRESEARCH AREA: AntimicrobialREFERENCES:M.E. Selsted, S.S.L. Harwig, T. Ganz, J.W. Schilling, and R.I. Lehrer, J. Clin. Invest., 76,1436 (1985). (Original)T. Ganz, M.E. Selsted, D. Szklarek, S.S.L. Harwig, K. Daher, D.F. Bainton, and R.I. Lehrer, J. Clin. Invest., 76,1427 (1985).(First Isolation)F.T. Lundy, D.F. Orr, C. Shaw, P.-J. Lamey, and G.J. Linden, Oral Oncol., 40, 139 (2004).C.B. Buck, P.M. Day, C.D. Thompson, J. Lubkowski, W. Lu, D.R. Lowy, a

ENCOMPASS
5

CPC Scientific H-Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys-OH (trifluoroacetate salt) 0.1MG
SDP

SEQUENCE: H-Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys-OH (trifluoroacetate salt)(Cys1 and 29 bridge, Cys3 and 18 bridge, Cys8 and 28 bridge)ONE-LETTER SEQUENCE: CYCRIPACIAGERRYGTCIYQGRLWAFCC (C1&C29 bridge, C3&C18 bridge, C8&C28 bridge)MOLECULAR FORMULA: C147H217N43O37S6MOLECULAR WEIGHT: 3370.95STORAGE CONDITIONS: -20 5 CCAS REGISTRY NUMBER: [99287-07-7]SYNONYMS: -Defensin-2 (Human), alpha-Defensin-2 (Human), Defensin HNP-2 humanRESEARCH AREA: AntimicrobialREFERENCES:M.E. Selsted, S.S.L. Harwig, T. Ganz, J.W. Schilling, and R.I. Lehrer, J. Clin. Invest., 76,1436 (1985). (Original)T. Ganz, M.E. Selsted, D. Szklarek, S.S.L. Harwig, K. Daher, D.F. Bainton, and R.I. Lehrer, J. Clin. Invest., 76,1427 (1985).(First Isolation)F.T. Lundy, D.F. Orr, C. Shaw, P.-J. Lamey, and G.J. Linden, Oral Oncol., 40, 139 (2004).C.B. Buck, P.M. Day, C.D. Thompson, J. Lubkowski, W. Lu, D.R. Lowy, a

ENCOMPASS